Výsledky vyhledávání - "A.-M Duliege"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

PF703 LONG-TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

Autor: N. Cooper, J. Bussel, D. Arnold, A.-M. Duliege, R. Boccia, H. Zayed, M. Boxer, S. Tong, M. Scholzberg, R. Numerof, D. Liles, Q. Hill

Publikováno v: HemaSphere. 3:306

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3ecda817ae404cf998af919d8c2fbf67
https://doi.org/10.1097/01.hs9.0000561096.37776.87

Zobrazit plný text záznamu

PF427 FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: INITIAL RESULTS OF THE OPEN-LABEL EXTENSION PERIOD OF THE SOAR PHASE 2 STUDY

Autor: S. Tong, C. Broome, A.-M. Duliege, K. Rogers, A. Lowe, A. Richy, R. Numerof, M. Boxer, H. Zayed, J. Field, D. Kuter, I. Murakhovskaya, D. Arnold

Publikováno v: HemaSphere. 3:167

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e714cb2842ca2f49823fa58cff55d2ec
https://doi.org/10.1097/01.hs9.0000559920.12010.ca

Zobrazit plný text záznamu

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

Publikováno v: The Journal of infectious diseases. 184(10)

Infants born to human immunodeficiency virus type 1 (HIV-1)-infected mothers were immunized at birth and at ages 4, 12, and 20 weeks with low-, medium-, or high-dose recombinant gp120 vaccine with MF59 adjuvant (HIV-1 SF-2 ; n = 52) or with MF59 alon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb85ffd218d10069b22663dd82375a7
https://pubmed.ncbi.nlm.nih.gov/11679925

Zobrazit plný text záznamu

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group

Autor: M J, McElrath, L, Corey, D, Montefiori, M, Wolff, D, Schwartz, M, Keefer, R, Belshe, B S, Graham, T, Matthews, P, Wright, G, Gorse, R, Dolin, P, Berman, D, Francis, A M, Duliege, D, Bolognesi, D, Stablein, N, Ketter, P, Fast

Publikováno v: AIDS research and human retroviruses. 16(9)

Several immunogens induce HIV-specific neutralization and in vitro lymphoproliferation in adults at low HIV-1 risk, but responses in persons at high HIV-1 risk are not known. We performed a multicenter, double-blinded, adjuvant-controlled trial with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f4b4abb6d58a14408f292e71b7e26d43
https://pubmed.ncbi.nlm.nih.gov/10875616

Zobrazit plný text záznamu

Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 32(5)

To determine the safety of 2 candidate vaccines against human immunodeficiency virus type 1 (HIV-1), a randomized, placebo-controlled, multicenter trial compared low, medium, and high doses of the vaccines or an adjuvant among infants born to HIV-inf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8873bba7ddcad8b3a303339bcb269215
https://pubmed.ncbi.nlm.nih.gov/11229849

Zobrazit plný text záznamu

Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators

Autor: W, Borkowsky, D, Wara, T, Fenton, J, McNamara, M, Kang, L, Mofenson, E, McFarland, C, Cunningham, A M, Duliege, D, Francis, Y, Bryson, S, Burchett, S A, Spector, L M, Frenkel, S, Starr, R, Van Dyke, E, Jimenez

Publikováno v: The Journal of infectious diseases. 181(3)

Children of mothers infected with human immunodeficiency virus type 1 (HIV-1) were immunized at birth and at 1, 3, and 5 months with 1 of 3 doses of recombinant gp120 vaccines prepared from SF-2 or MN strains of HIV-1. A total of 126 children were no

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::96dcc6db73fce8b426ab94e5c8ee9741
https://pubmed.ncbi.nlm.nih.gov/10720509

Zobrazit plný text záznamu

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120

Publikováno v: The Journal of infectious diseases. 183(4)

Elicitation of both memory cytotoxic T cell responses and human immunodeficiency virus (HIV)-neutralizing antibodies are desirable characteristics of an HIV vaccine regimen. We studied a combination vaccine regimen consisting of a canarypox (CP) vect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc1698ac17dbf19e7310c7fbc01bfd1
https://pubmed.ncbi.nlm.nih.gov/11170981

Zobrazit plný text záznamu

Interleukin-2 for the Treatment of Patients with HIV Disease

Autor: A.-M Duliege, S. J. Lowe, J. Maral, D. Sahner, T. A. Dover, M. J. Wolin, D. J. Sundin

Publikováno v: HIV-Infekt ISBN: 9783642640827

The course of HIV infection is marked by a progressive decline in CD4+ T-lymphocytes (CD4+ cells) and increasing viral load as a consequence of unchecked viral replication [1–9]. As CD4+ cells die, the repertoire of responses to foreign pathogens g

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4300fb6e3cf69fddcb1205957cd0ba68
https://doi.org/10.1007/978-3-642-59683-4_48

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání